[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
create a website
Retail Pharmacies and Drug Diversion during the Opioid Epidemic. (2020). Zhang, Xuan ; Janssen, Aljoscha.
In: Working Paper Series.
RePEc:hhs:iuiwop:1373.

Full description at Econpapers || Download paper

Cited: 5

Citations received by this document

Cites: 85

References cited by this document

Cocites: 30

Documents which have cited the same bibliography

Coauthors: 0

Authors who have wrote about the same topic

Citations

Citations received by this document

  1. .

    Full description at Econpapers || Download paper

  2. Entry regulation and competition evidence from retail and labor markets of pharmacists. (2021). Rostam-Afschar, Davud ; Unsorg, Maximiliane.
    In: University of Tübingen Working Papers in Business and Economics.
    RePEc:zbw:tuewef:146.

    Full description at Econpapers || Download paper

  3. Entry regulation and competition: Evidence from retail and labormarkets of pharmacists. (2021). Rostam-Afschar, Davud ; Unsorg, Maximiliane.
    In: Hohenheim Discussion Papers in Business, Economics and Social Sciences.
    RePEc:zbw:hohdps:032021.

    Full description at Econpapers || Download paper

  4. Entry Regulation and Competition: Evidence from Retail and Labor Markets of Pharmacists. (2021). Rostam-Afschar, Davud ; Unsorg, Maximiliane.
    In: GLO Discussion Paper Series.
    RePEc:zbw:glodps:836.

    Full description at Econpapers || Download paper

  5. .

    Full description at Econpapers || Download paper

References

References cited by this document

  1. (2009), ‘Variation in drug prices at pharmacies: Are prices higher in poorer areas?’, Health Services Research 44(2p1), 606–617.
    Paper not yet in RePEc: Add citation now
  2. (2014), ‘Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation’, Pharmacoepidemiology and Drug Safety 23(12), 1238–1246.
    Paper not yet in RePEc: Add citation now
  3. Alexander, G. C., Kruszewski, S. P. and Webster, D. W. (2012), ‘Rethinking opioid prescribing to protect patient safety and public health’, JAMA 308(18), 1865–1866.
    Paper not yet in RePEc: Add citation now

  4. Alpert, A. E., Evans, W. N., Lieber, E. M. and Powell, D. (2019), Origins of the opioid crisis and its enduring impacts, Technical report, National Bureau of Economic Research.

  5. Alpert, A., Lakdawalla, D. and Sood, N. (2015), Prescription drug advertising and drug utilization: The role of Medicare Part D, Technical report, National Bureau of Economic Research.

  6. Alpert, A., Powell, D. and Pacula, R. L. (2018), ‘Supply-side drug policy in the presence of substitutes: Evidence from the introduction of abuse-deterrent opioids’, American Economic Journal: Economic Policy 10(4), 1–35.

  7. Appold, K. (2019), Independent pharmacies: Not dead yet, Technical report, Drug Topics.
    Paper not yet in RePEc: Add citation now
  8. Ayres, I. and Jalal, A. (2018), ‘The impact of prescription drug monitoring programs on US opioid prescriptions’, The Journal of Law, Medicine & Ethics 46(2), 387–403.
    Paper not yet in RePEc: Add citation now
  9. Bach, P. and Hartung, D. (2019), ‘Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders’, Addiction Science & Clinical Practice 14(1), 30.
    Paper not yet in RePEc: Add citation now

  10. Bennett, V. M., Pierce, L., Snyder, J. A. and Toffel, M. W. (2013), ‘Customer-driven misconduct: How competition corrupts business practices’, Management Science 59(8), 1725–1742.

  11. Berry, P. H. and Dahl, J. L. (2000), ‘The new JCAHO pain standards: implications for pain management nurses’, Pain Management Nursing 1(1), 3–12.
    Paper not yet in RePEc: Add citation now
  12. Bolton, P., Freixas, X. and Shapiro, J. (2012), ‘The credit ratings game’, The Journal of Finance 67(1), 85–111.
    Paper not yet in RePEc: Add citation now
  13. Branco, F. and Villas-Boas, J. M. (2015), ‘Competitive vices’, Journal of Marketing Research 52(6), 801–816.
    Paper not yet in RePEc: Add citation now

  14. Buchmueller, T. C. and Carey, C. (2018), ‘The effect of prescription drug monitoring programs on opioid utilization in Medicare’, American Economic Journal: Economic Policy 10(1), 77–112.

  15. Butler, S. F., Cassidy, T. A., Chilcoat, H., Black, R. A., Landau, C., Budman, S. H. and Coplan, P. M. (2013), ‘Abuse rates and routes of administration of reformulated extended-release oxycodone: Initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment’, The Journal of Pain 14(4), 351–358.
    Paper not yet in RePEc: Add citation now

  16. Cai, H. and Liu, Q. (2009), ‘Competition and corporate tax avoidance: Evidence from chinese industrial firms’, The Economic Journal 119(537), 764–795.

  17. Capps, C., Dranove, D. and Ody, C. (2017), ‘Physician practice consolidation driven by small acquisitions, so antitrust agencies have few tools to intervene’, Health Affairs 36(9), 1556–1563.
    Paper not yet in RePEc: Add citation now
  18. CDC (2016), Pharmacists: On the front lines, Technical report.
    Paper not yet in RePEc: Add citation now
  19. CDC (2019b), ‘Risks of healthcare-associated infections from drug diversion: Injection safety | CDC’. URL: https: // www. cdc. gov/ injectionsafety/ drugdiversion/ index. html CDC (n.d.a), ‘National Vital Statistics System: Mortality statistics’.
    Paper not yet in RePEc: Add citation now
  20. Chilcoat, H. D., Coplan, P. M., Harikrishnan, V. and Alexander, L. (2016), ‘Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin)’, Drug and Alcohol Dependence 165, 221–228.
    Paper not yet in RePEc: Add citation now
  21. Cicero, T. J., Kurtz, S. P., Surratt, H. L., Ibanez, G. E., Ellis, M. S., Levi-Minzi, M. A. and Inciardi, J. A. (2011), ‘Multiple determinants of specific modes of prescription opioid diversion’, Journal of Drug Issues 41(2), 283–304.
    Paper not yet in RePEc: Add citation now
  22. Coplan, P. M., Chilcoat, H. D., Butler, S. F., Sellers, E. M., Kadakia, A., Harikrishnan, V., Haddox, J. D. and Dart, R. C. (2016), ‘The effect of an abuse-deterrent opioid formulation (oxycontin) on opioid abuse-related outcomes in the postmarketing setting’, Clinical Pharmacology & Therapeutics 100(3), 275–286.
    Paper not yet in RePEc: Add citation now

  23. Dafny, L. (2009), ‘Estimation and identification of merger effects: An application to hospital mergers ’, The Journal of Law and Economics 52(3), 523–550.

  24. Dafny, L., Ho, K. and Lee, R. S. (2019), ‘The price effects of cross-market mergers: theory and evidence from the hospital industry’, The RAND Journal of Economics 50(2), 286–325.

  25. Dart, R. C., Surratt, H. L., Cicero, T. J., Parrino, M. W., Severtson, S. G., Bucher-Bartelson, B. and Green, J. L. (2015), ‘Trends in opioid analgesic abuse and mortality in the United States’, New England Journal of Medicine 372(3), 241–248.
    Paper not yet in RePEc: Add citation now
  26. Dewatripont, M. and Tirole, J. (2019), ‘Incentives and ethics: How markets and organizations shape our moral behavior’.
    Paper not yet in RePEc: Add citation now
  27. Doleac, J., Mukherjoo, A. and Schnell, M. (2018), Research roundup: What does the evidence say about how to fight the opioid epidemic?, Technical report, Brookings Institute.
    Paper not yet in RePEc: Add citation now
  28. Dowell, D., Haegerich, T. M. and Chou, R. (2016), ‘CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016’, MMWR. Recommendations and Reports 65(No. RR-1), 1– 49.
    Paper not yet in RePEc: Add citation now
  29. Drug Enforcement Administration (2005), ‘Title 21 Code of Federal Regulations: Purpose of issue of prescription’.
    Paper not yet in RePEc: Add citation now

  30. Drugov, M. (2010), ‘Competition in bureaucracy and corruption’, Journal of Development Economics 92(2), 107–114.

  31. Eliason, P. J., Heebsh, B., McDevitt, R. C. and Roberts, J. W. (2019), ‘How acquisitions affect firm behavior and performance: Evidence from the dialysis industry’.
    Paper not yet in RePEc: Add citation now

  32. Evans, W. N., Lieber, E. M. and Power, P. (2019), ‘How the reformulation of OxyContin ignited the heroin epidemic’, Review of Economics and Statistics 101(1), 1–15.

  33. Falk, A. and Szech, N. (2013), ‘Morals and markets’, Science 340(6133), 707–711.
    Paper not yet in RePEc: Add citation now
  34. Fein, A. (2011a), 2010-2011 chain pharmacy industry profile, Technical report, Drug Channels Institute.
    Paper not yet in RePEc: Add citation now
  35. Fein, A. J. (2011b), ‘The pharmacy industry’s evolution: 2000 to 2010’.
    Paper not yet in RePEc: Add citation now

  36. Gowrisankaran, G., Nevo, A. and Town, R. (2015), ‘Mergers when prices are negotiated: Evidence from the hospital industry’, American Economic Review 105(1), 172–203.

  37. Habte, O., Holm, H. J. et al. (2017), ‘Competition makes inspectors more lenient: Evidence from the motor vehicle inspection market’, Department of Economics, Lund University Working Papers (2017: 19).

  38. Hadland, S. E., Rivera-Aguirre, A., Marshall, B. D. and Cerdá, M. (2019), ‘Association of pharmaceutical industry marketing of opioid products with mortality from opioid-related overdoses’, JAMA Network Open 2(1), e186007.
    Paper not yet in RePEc: Add citation now
  39. Haffajee, R. L. and Mello, M. M. (2017), ‘Drug companies’ liability for the opioid epidemic’, New England Journal of Medicine 377(24), 2301–2305.
    Paper not yet in RePEc: Add citation now
  40. Hagemeier, N. E., Gray, J. A. and Pack, R. P. (2013), ‘Prescription drug abuse: A comparison of prescriber and pharmacist perspectives’, Substance Use & Misuse 48(9), 761–768.
    Paper not yet in RePEc: Add citation now
  41. Hartung, D. M., Hall, J., Haverly, S. N., Cameron, D., Alley, L., Hildebran, C., O’Kane, N. and Cohen, D. (2018), ‘Pharmacists’ role in opioid safety: A focus group investigation’, Pain Medicine 19(9), 1799–1806.
    Paper not yet in RePEc: Add citation now
  42. Havens, J. R., Leukefeld, C. G., DeVeaugh-Geiss, A. M., Coplan, P. and Chilcoat, H. D. (2014), ‘The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers’, Drug and Alcohol Dependence 139, 9–17.
    Paper not yet in RePEc: Add citation now

  43. Hermalin, B. E. (1992), ‘The effects of competition on executive behavior’, The RAND Journal of Economics 23(3), 350–365.

  44. Hoffman, J. (2020), ‘Big pharmacy chains also fed the opioid epidemic, court filing says’, The New York Times .
    Paper not yet in RePEc: Add citation now
  45. Larochelle, M. R., Zhang, F., Ross-Degnan, D. and Wharam, J. F. (2015), ‘Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene’, JAMA Internal Medicine 175(6), 978–987.
    Paper not yet in RePEc: Add citation now
  46. Los Angeles Time (2019), ‘Florida ’pill mills’ were ’gas on the fire’ of opioid crisis’. Section: World & Nation.
    Paper not yet in RePEc: Add citation now

  47. Maclean, J. C., Mallatt, J., Ruhm, C. J. and Simon, K. (2020), Review of Economic Studies on the Opioid Crisis, Technical Report w28067, National Bureau of Economic Research.

  48. Mastropietro, D. J. and Omidian, H. (2015), ‘Abuse-deterrent formulations: Part 2: Commercial products and proprietary technologies’, Expert Opinion on Pharmacotherapy 16(3), 305–323.
    Paper not yet in RePEc: Add citation now
  49. Meinhofer, A. (2016), The war on drugs: Estimating the effect of prescription drug supply-side interventions, SSRN Scholarly Paper ID 2716974, Social Science Research Network, Rochester, NY.
    Paper not yet in RePEc: Add citation now

  50. Meinhofer, A. (2018), ‘Prescription drug monitoring programs: The role of asymmetric information on drug availability and abuse’, American Journal of Health Economics 4(4), 504–526.

  51. National Institute on Drug Abuse (2017), ‘CME/CE Activities’.
    Paper not yet in RePEc: Add citation now
  52. NSDUH (2018), ‘Key substance use and mental health indicators in the united states: Results from the 2017 National Survey on Drug Use and Health’, National Survey on Drug Use and Health .
    Paper not yet in RePEc: Add citation now
  53. Okie, S. (2010), ‘A flood of opioids, a rising tide of deaths’, New England Journal of Medicine 363(21), 1981–1985.
    Paper not yet in RePEc: Add citation now

  54. Pacula, R. L. and Powell, D. (2018), ‘A supply-side perspective on the opioid crisis’, Journal of Policy Analysis and Management 37(2), 438–446.

  55. Paulozzi, L. J., Mack, K. A. and Hockenberry, J. M. (2014), ‘Vital signs: variation among states in prescribing of opioid pain relievers and benzodiazepines—United States, 2012’, MMWR: Morbidity and Mortality Weekly Report 63(26), 563.
    Paper not yet in RePEc: Add citation now
  56. Peirce, G. L., Smith, M. J., Abate, M. A. and Halverson, J. (2012), ‘Doctor and pharmacy shopping for controlled substances’, Medical Care 50(6), 494–500.
    Paper not yet in RePEc: Add citation now
  57. Pharmacists Mutual (2016), Pharmacy Crime A look at pharmacy burglary and robbery in the United States and the strategies and tactics needed to manage the problem., Technical report.
    Paper not yet in RePEc: Add citation now

  58. Powell, D., Pacula, R. L. and Taylor, E. (2015), How increasing medical access to opioids contributes to the opioid epidemic: Evidence from Medicare Part D, Technical report, National Bureau of Economic Research.

  59. Quinones, S. (2015), Dreamland: The true tale of America’s opiate epidemic, Bloomsbury Publishing USA.
    Paper not yet in RePEc: Add citation now
  60. Rich, S., Ba Tran, A. and Williams, A. (2019), ARCOS: Load ARCOS Prescription Data Prepared by the Washington Post. R package version 0.8.2. URL: https: // CRAN. R-project. org/ package= arcos Schnell, M. (2017), Physician behavior in the presence of a secondary market: The case of prescription opioids, Technical report, University of Princeton.
    Paper not yet in RePEc: Add citation now
  61. Schnell, M. (2019), ‘The opioid crisis: Tragedy, treatments and trade-offs’, Policy Brief: Stanford Institute for Economic Policy Research .
    Paper not yet in RePEc: Add citation now

  62. Schnell, M. and Currie, J. (2018), ‘Addressing the opioid epidemic: Is there a role for physician education?’, American Journal of Health Economics 4(3), 383–410.

  63. Schommer, J. (2013), APhA Career Pathway Evaluation Program for Pharmacy Professionals 2012 Pharmacist Profile Survey, Technical report, American Pharmacists Association (APhA).
    Paper not yet in RePEc: Add citation now
  64. Severtson, S. G., Bartelson, B. B., Davis, J. M., Muñoz, A., Schneider, M. F., Chilcoat, H., Coplan, P. M., Surratt, H. and Dart, R. C. (2013), ‘Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010’, The Journal of Pain 14(10), 1122–1130.
    Paper not yet in RePEc: Add citation now

  65. Shleifer, A. (2004), ‘Does competition destroy ethical behavior?’, American Economic Review 94(2), 414–418.

  66. Simeone, R. (2017), ‘Doctor shopping behavior and the diversion of prescription opioids’, Substance abuse: research and treatment 11, 1178221817696077.
    Paper not yet in RePEc: Add citation now
  67. Simon, L. S. (2012), ‘Relieving pain in America: A blueprint for transforming prevention, care, education, and research’, Journal of Pain & Palliative Care Pharmacotherapy 26(2), 197–198.
    Paper not yet in RePEc: Add citation now

  68. Snyder, J. (2010), ‘Gaming the liver transplant market’, The Journal of Law, Economics, & Organization 26(3), 546–568.

  69. Soffin, E. M., Waldman, S. A., Stack, R. J. and Liguori, G. A. (2017), ‘An evidence-based approach to the prescription opioid epidemic in orthopedic surgery’, Anesthesia & Analgesia 125(5), 1704–1713.
    Paper not yet in RePEc: Add citation now
  70. Substance Abuse and Mental Health Services Administration (2013), Association of nonmedical pain reliever use and initiation of heroin use in the United States, Technical report.
    Paper not yet in RePEc: Add citation now
  71. URL: https: // doi. org/ 10. 1517/ 14656566. 2014. 970175 Meara, E., Horwitz, J. R., Powell, W., McClelland, L., Zhou, W., O’Malley, A. J. and Morden, N. E. (2016), ‘State legal restrictions and prescription-opioid use among disabled adults’, New England Journal of Medicine 375(1), 44–53.
    Paper not yet in RePEc: Add citation now
  72. URL: https: // www. cdc. gov/ drugoverdose/ maps/ rxrate-maps. html , year=2020, Chaffee, B. (2019), ‘Communities are losing independent pharmacies’.
    Paper not yet in RePEc: Add citation now
  73. URL: https: // www. cdc. gov/ drugoverdose/ pdf/ pharmacists_ brochure-a. pdf CDC (2019a), ‘America’s drug overdose epidemic: Data to action’, Centers for Disease Control and Prevention .
    Paper not yet in RePEc: Add citation now
  74. URL: https: // www. cdc. gov/ nchs/ nvss/ deaths. htm? CDC_ AA_ refVal= https% 3A% 2F% 2Fwww. cdc. gov% 2Fnchs% 2Fdeaths. htm , year=2020, CDC (n.d.b), ‘U.S. opioid prescribing rate maps’.
    Paper not yet in RePEc: Add citation now
  75. URL: https: // www. deadiversion. usdoj. gov/ 21cfr/ cfr/ 1306/ 1306_ 04. htm Drug Enforcement Administration and others (2010), ‘Pharmacist’s manual: An informational outline of the Controlled Substances Act’, Springfield: United States Department of Justice, Drug Enforcement Administration, Office of Diversion Control .
    Paper not yet in RePEc: Add citation now

  76. URL: https: // www. drugabuse. gov/ nidamed-medical-health-professionals/ health-professions-education/ cmece-activities Nguyen, T., Bradford, W. D. and Simon, K. (2019), How do Opioid Prescribing Restrictions Affect Pharmaceutical Promotion? Lessons from the Mandatory Access Prescription Drug Monitoring Programs, Technical Report w26356, National Bureau of Economic Research, Cambridge, MA.

  77. URL: https: // www. latimes. com/ world-nation/ story/ 2019-07-20/ florida-pill-mills-opioid-crisis Luo, J., Kulldorff, M., Ameet Sarpatwari, J., Pawar, A. and Kesselheim, A. S. (2019), ‘Variation in prescription drug prices by retail pharmacy type’, Annals of Internal Medicine 171, 605–611.
    Paper not yet in RePEc: Add citation now

  78. URL: https: // www. nytimes. com/ 2020/ 05/ 27/ health/ opioids-pharmacy-cvs-litigation. html Inciardi, J. A., Surratt, H. L., Kurtz, S. P. and Cicero, T. J. (2007), ‘Mechanisms of prescription drug diversion among drug-involved club- and street-based populations’, Pain Medicine 8(2), 171– 183.

  79. URL: https: // www. pharmacist. com/ sites/ default/ files/ files/ Profile_ 16% 20Independent% 20FINAL% 20071213. pdf Schommer, J., Brown, L. and Sogol, E. (2007), Career Pathway Evaluation Program 2007 Pharmacist Profile Survey, Technical report, American Pharmacists Association (APhA). URL: https: // www. pharmacist. com/ sites/ default/ files/ files/ Profile_ 06_ chain_ pharmacy-staff. pdf Sessler, N. E., Downing, J. M., Kale, H., Chilcoat, H. D., Baumgartner, T. F. and Coplan, P. M.
    Paper not yet in RePEc: Add citation now

  80. URL: https://bettermymeds.com/2019/08/30/communities-are-losing-independent-pharmacies/ Chen, J. (2019), ‘The effects of competition on prescription payments in retail pharmacy markets’, Southern Economic Journal 85(3), 865–898.

  81. URL: https://www.phmic.com/wp-content/uploads/2016/07/PMCCrimeReport.pd f Pharmacy Times (2018), Pharmacy wars: An era of acquisition, mergers, and losses, Technical report, Pharmacy Times.
    Paper not yet in RePEc: Add citation now

  82. Van Zee, A. (2009), ‘The promotion and marketing of OxyContin: Commercial triumph, public health tragedy’, American Journal of Public Health 99(2), 221–227.

  83. Watkins, E. A., Wollan, P. C., Melton III, L. J. and Yawn, B. P. (2008), ‘A population in pain: Report from the Olmsted County health study’, Pain Medicine 9(2), 166–174.
    Paper not yet in RePEc: Add citation now
  84. Yang, Z., Wilsey, B., Bohm, M., Weyrich, M., Roy, K., Ritley, D., Jones, C. and Melnikow, J. (2015), ‘Defining risk of prescription opioid overdose: Pharmacy shopping and overlapping prescriptions among long-term opioid users in Medicaid’, The Journal of Pain 16(5), 445–453.
    Paper not yet in RePEc: Add citation now
  85. Zhu, P., Hilsenrath, P. E. et al. (2015), ‘Mergers and acquisitions in us retail pharmacy’, Journal of Health Care Finance 41(3).
    Paper not yet in RePEc: Add citation now

Cocites

Documents in RePEc which have cited the same bibliography

  1. The cost of influence: How gifts to physicians shape prescriptions and drug costs. (2024). Valente, Marica ; Newham, Melissa.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:95:y:2024:i:c:s0167629624000328.

    Full description at Econpapers || Download paper

  2. Health Crisis and Housing Market Effects - Evidence from the U.S. Opioid Epidemic. (2023). Thibodeau, Mark ; Dlima, Walter.
    In: The Journal of Real Estate Finance and Economics.
    RePEc:kap:jrefec:v:67:y:2023:i:4:d:10.1007_s11146-021-09884-8.

    Full description at Econpapers || Download paper

  3. The Cost of Influence:How Gifts to Physicians Shape Prescriptions and Drug Costs. (2023). Valente, Marica ; Newham, Melissa.
    In: Working Papers.
    RePEc:inn:wpaper:2023-03.

    Full description at Econpapers || Download paper

  4. .

    Full description at Econpapers || Download paper

  5. Behavioral Responses to Supply-Side Drug Policy During the Opioid Epidemic. (2022). Sherry, Tisamarie B ; Maestas, Nicole ; Liebert, Helge ; Balestra, Simone.
    In: IZA Discussion Papers.
    RePEc:iza:izadps:dp15221.

    Full description at Econpapers || Download paper

  6. Choices and Implications when Measuring the Local Supply of Prescription Opioids. (2022). Montes, Joshua ; Mezza, Alvaro ; Cho, David.
    In: Finance and Economics Discussion Series.
    RePEc:fip:fedgfe:2022-78.

    Full description at Econpapers || Download paper

  7. Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal. (2022). Skira, Meghan ; Lawler, Emily C.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:81:y:2022:i:c:s0167629621001429.

    Full description at Econpapers || Download paper

  8. Mortality during resource booms and busts. (2022). Hill, Elaine ; Boslett, Andrew.
    In: Journal of Environmental Economics and Management.
    RePEc:eee:jeeman:v:115:y:2022:i:c:s0095069622000614.

    Full description at Econpapers || Download paper

  9. Behavioral Responses to Supply-Side Drug Policy During the Opioid Epidemic. (2022). Sherry, Tisamarie B ; Maestas, Nicole ; Liebert, Helge ; Balestra, Simone.
    In: CESifo Working Paper Series.
    RePEc:ces:ceswps:_9704.

    Full description at Econpapers || Download paper

  10. Who pays for gifts to physicians? Heterogeneous effects of industry payments on drug costs. (2022). Newham, Melissa ; Valente, Marica.
    In: Papers.
    RePEc:arx:papers:2203.01778.

    Full description at Econpapers || Download paper

  11. .

    Full description at Econpapers || Download paper

  12. The effect of medical cannabis laws on pharmaceutical marketing to physicians. (2021). Lebesmuehlbacher, Thomas ; Smith, Rhet A.
    In: Health Economics.
    RePEc:wly:hlthec:v:30:y:2021:i:10:p:2409-2436.

    Full description at Econpapers || Download paper

  13. The Opioid Epidemic: Causes and Consequences. (2021). Barone, Victoria ; Cabrales, Carolina Arteaga .
    In: Working Papers.
    RePEc:tor:tecipa:tecipa-698.

    Full description at Econpapers || Download paper

  14. Behavioral Responses to Supply-Side Drug Policy During the Opioid Epidemic. (2021). Sherry, Tisamarie B ; Maestas, Nicole ; Liebert, Helge ; Balestra, Simone.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:29596.

    Full description at Econpapers || Download paper

  15. Labor Market Effects of the Oxycodone-Heroin Epidemic. (2021). Garcia, Daniel ; Cho, David ; Weingarden, Alison E.
    In: Finance and Economics Discussion Series.
    RePEc:fip:fedgfe:2021-25.

    Full description at Econpapers || Download paper

  16. Drug firms’ payments and physicians’ prescribing behavior in Medicare Part D. (2021). Miller, Sarah ; Carey, Colleen.
    In: Journal of Public Economics.
    RePEc:eee:pubeco:v:197:y:2021:i:c:s0047272721000384.

    Full description at Econpapers || Download paper

  17. Is the rise in illicit opioids affecting labor supply and disability claiming rates?. (2021). Powell, David ; Park, Sujeong.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:76:y:2021:i:c:s0167629621000151.

    Full description at Econpapers || Download paper

  18. Can electronic prescribing mandates reduce opioid-related overdoses?. (2021). Powell, David ; Abouk, Rahi.
    In: Economics & Human Biology.
    RePEc:eee:ehbiol:v:42:y:2021:i:c:s1570677x21000241.

    Full description at Econpapers || Download paper

  19. When Innovation Goes Wrong: Technological Regress and the Opioid Epidemic. (2021). Glaeser, Edward L ; Cutler, David M.
    In: Journal of Economic Perspectives.
    RePEc:aea:jecper:v:35:y:2021:i:4:p:171-96.

    Full description at Econpapers || Download paper

  20. .

    Full description at Econpapers || Download paper

  21. Opium Price Shocks and Prescription Opioids in the US. (2020). Nistic, R ; Giua, L ; Deiana, C.
    In: Health, Econometrics and Data Group (HEDG) Working Papers.
    RePEc:yor:hectdg:20/23.

    Full description at Econpapers || Download paper

  22. Is the Rise in Illicit Opioids Affecting Labor Supply and Disability Claiming Rates?. (2020). Powell, David ; Park, Sujeong.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:27804.

    Full description at Econpapers || Download paper

  23. The Opioid Epidemic Was Not Caused by Economic Distress But by Factors that Could be More Rapidly Addressed. (2020). Schwandt, Hannes ; Currie, Janet.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:27544.

    Full description at Econpapers || Download paper

  24. The Evolving Consequences of OxyContin Reformulation on Drug Overdoses. (2020). Powell, David ; Pacula, Rosalie.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:26988.

    Full description at Econpapers || Download paper

  25. Drug Firms Payments and Physicians Prescribing Behavior in Medicare Part D. (2020). Miller, Sarah ; Lieber, Ethan ; Carey, Colleen.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:26751.

    Full description at Econpapers || Download paper

  26. Retail Pharmacies and Drug Diversion during the Opioid Epidemic. (2020). Zhang, Xuan ; Janssen, Aljoscha.
    In: Working Paper Series.
    RePEc:hhs:iuiwop:1373.

    Full description at Econpapers || Download paper

  27. The relationship of opioid prescriptions and the educational performance of children. (2020). Ozturk, Orgul D ; Gordanier, John M ; Cotti, Chad D.
    In: Social Science & Medicine.
    RePEc:eee:socmed:v:265:y:2020:i:c:s0277953620306250.

    Full description at Econpapers || Download paper

  28. The Economics behind the Epidemic: Afghan Opium Price and Prescription Opioids in the US. (2019). Nisticò, Roberto ; Nistico, Roberto ; Giua, Ludovica ; Deiana, Claudio.
    In: IZA Discussion Papers.
    RePEc:iza:izadps:dp12872.

    Full description at Econpapers || Download paper

  29. .

    Full description at Econpapers || Download paper

Coauthors

Authors registered in RePEc who have wrote about the same topic

Report date: 2024-12-28 12:53:26 || Missing content? Let us know

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated October, 6 2023. Contact: CitEc Team.